Critical evaluation of bispecific antibodies as targetins agents for boron neutron capture therapy of brain tumors

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2581-2587

  Liu, Liang ^a   Barth, Rolf F ^a   Adams, Dianne M ^a   Soloway, Albert H ^a   Reisfeld, Ralph A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Bispecific antibody; Boron neutron capture therapy; Brain tumors; Polyhedral boranes

Indexed keywords

BISPECIFIC ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; BRAIN TUMOR; GLIOMA CELL; MELANOMA CELL; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; FEASIBILITY STUDIES; GLIOBLASTOMA; HUMANS; IODINE RADIOISOTOPES; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; RATS; TUMOR CELLS, CULTURED;

EID: 0029954945     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Barth RF, Soloway AH and Fairchild RG: Boron neutron capture therapy for cancer: realities and prospects. Cancer 70: 2995-3007, 1992.
2. Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl 32: 950-984, 1993.
3. Soloway AH, Barth RF and Carpenter DE (eds): Advances in Neutron Capture Therapy. New York, Plenum Press, 1993.
4. Zamenhof R, Solares G, Harling O (eds): Topics in Dosimetry & Treatment Planning for Neutron Capture Therapy. Madison, WI, Advanced Medical Publishing, 1994.
5. Barth RF, Adams DM, Solovay AH, Alam F and Darby MV: Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem 5: 58-66, 1994.
6. Fanger MW (ed): Bispecific Antibodies RG Landis Company, Austin. TX, 1995.
7. Nisonoff A and Rivers MM: Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 93: 460-462, 1961.
8. Karpovsky B, Titus JA, Stephany DA and Segal DM: Production of target specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ receptor antibodies. J Exp Med 160: 1686-1701, 1984.
9. 2 antibody containing thioether-linked Fab′γ fragments. J Immunol 139: 2367-2375, 1987.
10. Reading CL: Procedures for in vitro immunization and monoclonal antibody production. In: BH Tom and JP Allison (eds), Hybridomas and Cellular Immortality pp 235-250. NewYork, Plenum Press, 1983.
11. Tiebout RF, Van Bostel-Oosterhof F, Stricker EAM and Zeulemaker WP: A human hybrid hybridoma. J Immunol 139: 3402-3405, 1987.
12. Karawajew L, Micheel B, Behrsing O and Gaestel M: Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter J Immunol Methods 96: 265-270, 1987.
13. Urnovitz HB, Chang Y, Scott M, Fleischman J and Lynch RG: IgA:IgM and IgA:IgA hybrid hybridomas secrete heteropolymeric immunoglobulins that are polyvalent and bispecific. J Immunol 140: 558-563, 1988.
14. Milstein C and Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540, 1983.
15. Webb KS, Ware JL, Parks SF, Walther PJ and Paulson DF: Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by on antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy. Cancer Treatment Rep 69: 663-672, 1985.
16. Morrison SL, Johnson MJ, Herzenberg LA and Oi VT: Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U.S.A. 81: 6851-6855, 1984.
17. Boulianne GL, Houzumi N and Shulman MJ: Production of functional chimeric mouse/human antibody. Nature 312: 643-646, 1984.
18. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG and Rabbitts TH: A hapten-specific chimeric IgE antibody with human physiological effector function. Nature 314: 268-270, 1985.
19. Jones PT, Dear PH, Foote J, Neuberger MS and Winter G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525 1986.
20. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R and Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U.S.A. 85: 5879-5883, 1988.
21. Bird RE, Hardman D, Jacobson JW, Johnson S, Kaufman BE, Lee SM, Pope SH, Riordan GS and Whitlow M: Single-chain antigen-binding proteins. Science 242: 423-426, 1988.
22. Songsivilai S, Clissold PM and Lachmann PJ: A novel strategy for producing chimeric bispecific antibodies by gene transfection. Biochem Res Commun 64: 271-276, 1989.
23. Renner C and Pfreundshuh M: Tumor therapy by immune recruitment with bispecific antibodies. Immunol Reviews 145: 179-209, 1995.
24. Staerz UD, Kanagawa O and Bevan MJ: Hybrid antibodies can target sites for attack by T cells. Nature 314: 628-631, 1985.
25. Barr IG, McDonald HR, Buchegger F and Von Fliedner V: Lysis of tumor cells by the retargeting of murine cytolytic T lymphocyte; with bispecific antibodies. Int J Cancer 40: 423-429, 1987.
26. Vyakamam A, Strangeways AL, Glover RE and Lachmann PJ: Cytolysis by cloned helper T cells: induction by specific antigen or by anti-CD3 hybrid antibodies. Scand J Immunol 27: 635-644, 1988.
27. Nitta T, Sato K, Okumura K and Ishii S: Induction of cytotoxicity in human T cells coated with anti-glioma X anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72: 476-481, 1990.
28. Corvalan JRF, Smith W, Gore VA and Brandon DR: Specific in vitro and in vivo drug localization of tumor cells using a hybrid-hybrid monoclonal antibody recognizing both carcinoembryonic antigen (CEA) and vincal alkloids. Cancer Immunol Immunother 24: 133-137 1987.
29. Tsukada Y, Ohkawa K, Hibi N, Tsuzuki K, Oguma K and Satoh H: The effect of bispecific monoclonal antibody recognizing both hepatoma specific membrane glycoprotein and anthracyclin drugs on the metastatic growth of hepatoma AH66. Cancer Biochem Biophys 10: 247-256, 1989.
30. Tazzaru PL, Zhang S, Chen Q, Sforzini S, Bolognesi A, Stirpe F, Xie H, Moretta A and Ferrini S: Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation. Br J Cancer 67: 1248-1253, 1993.
31. Liu L, Adams DM, Barth RF and Soloway AH: Production of monoclonal antibodies (MoAbs) reactive with boronated isocyanate for BNCT. Proc Am Assoc Cancer Res 34: 474, 1993.
32. Liu L, Barth RF, Adams DM, Soloway AH and Reisfeld RA: Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J Hematotherapy 4: 477-483 1995.
33. Schrappe M Klier GF Spiro RC Walts TA and Reisfeld RA: Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51: 4986-4993, 1991.
34. Staez UD and Bevan MJ: Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U.S.A. 83: 1453-1457, 1986.
35. Darby CR, Hamano K and Wood KJ: Purification of monoclonal antibodies from tissue culture medium depleted of IgG. J Immunol Methods 159: 125-129, 1993.
36. Tan-Wilson AL, Reichlin M and Noble RW: Isolation and characterization of low and high affinity goat antibodies directed to single antigenic sites on human hemoglobin. Immunochemistry 13: 921-927, 1977.
37. Gonyea LM: Purification and iodination of antibody for use in an immunoradiometric assay for serum ferritin. Clin Chem 23: 234-236 1977.
38. Laemli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
39. Douillard JY and Huffman T: Enzyme-linked immunosorbent assay for screening monoclonal antibody production using enzyme-labeled second antibody. Methods in Fnzymology 92: 168-174, 1983.
40. Wick G, Traill KN and Schauenstein K (eds): Immunofluorescence Technology pp 325-327, Amsterdam, Elsevier Biomedical Press, 1982.
41. Scatchard G: The attractions of proteins for small molecules and ions. Ann N.Y. Acad Sci 51: 660-672, 1949.
42. Bullard DE, Schold SC, Bigner SH and Bigner DD: Growth and chemotherapeutic responses in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40: 410-427, 1981.
43. Schold SC Jr, Bullard DE, Bigner SH, Jones TR and Bigner DD: Growth, morphology and serial transplantation of anaplastic human gliomas in athymic mice. J Neuro-Oncol 1: 5-14 1983.
44. Bullard DE, Adams CJ, Coleman RE and Bigner DD: In vitro imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. J Neurosurg 6: 257-262, 1986.
45. Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach J-P, Coakham HB, Tribolet Nde, Bullard DE, Zalutsky MR and Bigner DD: Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J Neuroimmunol 15: 37-56 1987.
46. Steel RGD and Torrie JH (eds): Principles and Procedures of Statistics. New York, McGraw-Hill Inc, 1980.
47. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosile H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
48. Javid M, Brownell GL and Sweet WH: The possible use of neutron-capture isotopes such as boron-10 in the treatment of neoplasms: II. computation of the radiation energy and estimates of effects in normal and neoplastic brain. J Clin Invest 31: 603-610, 1952.
49. Dewey WC, Ling CC and Meyn RE: Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiation Oncology Biol Phys 33: 781-796 1995.
50. Yang WL, Barth RF, Carpenter DE, Moeschberger ML and Goodman JH: Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood brain barrier disruption. Neurosurg 38: 985-992, 1996.
51. Hatanaka H and Nakagawa Y: Clinical results of long-surviving brain tumor patients who underwent boron capture therapy. Int J Radiation Oncology Biol Phys 28: 1061-1066, 1994.
52. Coderre JA, Elositz EH, Chadha M, Bergland R, Capala J, Joel DD, Liu HB, Slatkin DN and Chanana AD: Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neuro-oncology. (In Press) 1996.
53. Bonino LD, De Monte BD, Spagnoli GC, Vola R, Mariani M, Barone D, Moro AM, Riva P, Nicotra MR, Natali PG and Malavasi F: Bispecific monoclonal antibody ant-CD3 × anti-terrascin: an immunotherapeutic agent for human glioma. Int J Cancer 61: 509-515, 1995.